BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 3552348)

  • 21. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
    Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D
    Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
    Gore SD; Weng LJ; Jones RJ; Cowan K; Zilcha M; Piantadosi S; Burke PJ
    Clin Cancer Res; 1995 Mar; 1(3):295-303. PubMed ID: 9815985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Runde V; de Witte T; Arnold R; Gratwohl A; Hermans J; van Biezen A; Niederwieser D; Labopin M; Walter-Noel MP; Bacigalupo A; Jacobsen N; Ljungman P; Carreras E; Kolb HJ; Aul C; Apperley J
    Bone Marrow Transplant; 1998 Feb; 21(3):255-61. PubMed ID: 9489648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Diagnosis and therapy strategy in myelodysplastic syndromes].
    Gattermann N; Aul C
    Praxis (Bern 1994); 1996 Jan; 85(3):39-44. PubMed ID: 8578048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Differentiation therapy for myelodysplastic syndrome].
    Hino K; Nakamaki T
    Rinsho Ketsueki; 1993 Mar; 34(3):283-8. PubMed ID: 7683064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autologous stem cell transplantation in myelodysplastic syndromes.
    de Witte T; Suciu S; Brand R; Muus P; Kröger N
    Semin Hematol; 2007 Oct; 44(4):274-7. PubMed ID: 17961727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in supportive care of myelodysplastic syndromes.
    Gordon MS
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):21-4. PubMed ID: 10530713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group.
    Arnold R; de Witte T; van Biezen A; Hermans J; Jacobsen N; Runde V; Gratwohl A; Apperley JF
    Bone Marrow Transplant; 1998 Jun; 21(12):1213-6. PubMed ID: 9674854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
    Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
    Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
    Shi J; Shao Z; Liu H; Li K; Song L; Zhang Y; Zheng Y; Chen G; Chu Y; He H; Zhao M; He G; Feng B; Hao Y; Yang T; Yang C
    Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nursing care of the patient receiving subcutaneous low-dose Ara-C therapy.
    Sticklin LA; Dubbelde K; Larson E
    Oncol Nurs Forum; 1989; 16(3):365-9. PubMed ID: 2734216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Myeloproliferative syndromes].
    Ganser A
    Ther Umsch; 1996 Feb; 53(2):97-102. PubMed ID: 8629270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myelodysplastic syndromes: a review for nurses.
    Cain J; Hood-Barnes J; Spangler J
    Oncol Nurs Forum; 1991; 18(1):113-7. PubMed ID: 2003103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical investigation of interferons in the preleukemic state (CML and MDS)].
    Koyama S
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1191-7. PubMed ID: 3132893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myelodysplastic syndrome.
    Hofmann WK; Koeffler HP
    Annu Rev Med; 2005; 56():1-16. PubMed ID: 15660498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current treatment options for myelodysplastic syndromes].
    Nolte F; Hofmann WK
    Dtsch Med Wochenschr; 2010 Sep; 135(38):1863-9. PubMed ID: 20842606
    [No Abstract]   [Full Text] [Related]  

  • 39. Preleukaemia and myelodysplastic syndromes today.
    Jacobs A
    Recenti Prog Med; 1989 Oct; 80(10):501-7. PubMed ID: 2690216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complications and treatment of the myelodysplastic syndromes.
    Tricot GJ
    Leuk Res; 1992; 16(1):117-21. PubMed ID: 1732664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.